Astellas Pharma has signed a memorandum of understanding (MoU) with UMN Pharma to co-develop and exclusively commercialise UMN’s cell culture-based influenza vaccines in Japan’s lucrative flu drug market.

Under the MoU, Astellas gains the rights for the UMN-0501 and UMN-0502 drug programmes in Japan. Financial details of the deal were not disclosed.

UMN-0501 is a cell culture-based H5N1 avian influenza vaccine that was granted orphan drug status in June 2008. It achieved subsequent successful Phase I and II clinical trials, confirming its immunogencity and safety.

UMN-0502 is a cell culture-based seasonal influenza vaccine based on three different antigens, which is currently pending a Phase I/II clinical trial programme in Japan.

The companies plan to launch the two vaccines by the end of 2014.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData